一个多参数的风险表,为失去了类风湿性关节炎患者的临床缓解状态:一个STARTER研究后 hoc分析
Simone Perniola1,2, Stefano Alivernini1,3,4, Elisa Gremese1,2,4
1Immunology Research Core Facility, Gemelli Science and Technology Park (GSTeP) - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Rheumatology (Oxford, England)
|February 16, 2024
概括
类风湿性关节炎 (RA) 缓解期患者可以使用新工具预测疾病爆发. 该模型确定了关键的临床和超声波特征,以便在12个月内预测爆发.
科学领域:
- 类风湿病学 类风湿病学
- 医疗成像医学成像
背景情况:
- 类风湿性关节炎 (RA) 是一种慢性自身免疫性疾病,其特征是关节炎症.
- 在RA中维持临床缓解对于长期结果至关重要.
- 预测在缓解期的RA患者中疾病爆发对于主动管理至关重要.
研究的目的:
- 确定临床和肌肉骨超声学 (MSUS) 特征,预测缓解期的RA患者的疾病爆发.
- 开发一种预测模型和风险表,用于RA缓解中疾病爆发的概率.
主要方法:
- 从参与389名RA患者的DAS28定义缓解的STARTER研究中对数据进行后期分析.
- 肌肉骨超声波 (MSUS) 根据OMERACT指南进行.
- 后勤回归分析以确定疾病爆发的重要预测因素.
主要成果:
- 35%的RA患者在12个月内经历了疾病爆发.
- 爆发的预测因素包括ACPA阳性,在基线持续的临床缓解,以及膜功率多普勒信号.
- 一个预测模型显示,疾病爆发的调整几率比为3.064 .
结论:
- 开发了一个多参数风险表,以预测门诊机构的RA疾病爆发.
- 这种适应性爆发预测模型可能有助于为缓解期的RA患者定义治疗策略.
- 需要外部验证来确认该工具的实用性.
相关概念视频
Hazard Ratio
122
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
122
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
126
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
126
Relative Risk
170
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
170
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
163
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
163
Receiver Operating Characteristic Plot
172
A ROC (Receiver Operating Characteristic) plot is a graphical tool used to assess the performance of a binary classification model by illustrating the trade-off between sensitivity (true positive rate) and specificity (false positive rate). By plotting sensitivity against 1 - specificity across various threshold settings, the ROC curve shows how well the model distinguishes between classes, with a curve closer to the top-left corner indicating a more accurate model. The area under the ROC curve...
172
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137


